Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

RARE PHOTOS: Longeveron | Vintage Vibes

A $30 Million Reason to Buy Penny Stock Longeveron Today

Longeveron shares rip higher as the biotech firm raises $30 million via a private placement. Here’s why it may not be too late to invest in LGVN stock yet.

Barchart · Mar 11

EXCLUSIVE: Longeveron's Lomecel-B Product Gets US FDA Fast Track Designation For Treatment Of Hypoplastic Left Heart Syndrome in Infants

The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to Longeveron Inc (NASDAQ: LGVN) Lomecel-B for the treatment of Hypoplastic Left Heart Syndrome (HLHS).

Benzinga · Aug 31, 2022

LGVN: Alzheimer's Study Gains Traction as CEO Search Continues

By Brad Sorensen, CFA NASDAQ:LGVN READ THE FULL LGVN RESEARCH REPORT

Benzinga · Jul 27, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

LGVN: CEO Leaving but Progress Continues

By Brad Sorensen, CFA NASDAQ:LGVN READ THE FULL LGVN RESEARCH REPORT

Benzinga · May 13, 2022

Recap: Longeveron Q1 Earnings

Longeveron (NASDAQ:LGVN) reported its Q1 earnings results on Friday, May 13, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Benzinga · May 13, 2022

Longeveron's Earnings: A Preview

Longeveron (NASDAQ:LGVN) is set to give its latest quarterly earnings report on Friday, 2022-05-13. Here's what investors need to know before the announcement. Analysts estimate that Longeveron will report an earnings per share (EPS) of $-0.22.

Benzinga · May 12, 2022

The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga · May 10, 2022

Read news from The Economist, FT, and more,
with one subscription

EXCLUSIVE: Longeveron Adds Miami Veterans Affairs Site To Its Ongoing Mid-Stage Alzheimer's Trial

Longeveron Inc (NASDAQ: LGVN) has announced a Cooperative Research and Development Agreement (CRADA) with the United States Department of Veterans Affairs (VA) to add Miami VA clinical site to its ongoing Phase 2 Alzheimer’s Disease (AD) trial.

Benzinga · Apr 13, 2022

5 Short Squeeze Candidates To Watch: Aterian Tops The List, System1 Group And Longeveron Join Leaderboard

Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move.

Benzinga · Apr 11, 2022

12 Health Care Stocks Moving In Tuesday's Intraday Session

Benzinga · Apr 5, 2022

LGVN: LGVN Publishes Positive Alzheimer's Results

By Brad Sorensen, CFA NASDAQ:LGVN READ THE FULL LGVN RESEARCH REPORT

Benzinga · Apr 1, 2022

Why Longeveron Shares Are Surging Today

Longeveron Inc (NASDAQ: LGVN) shares are trading higher Thursday after the company announced the publication of results from a Phase 1 trial testing Lomecel-B on patients with mild Alzheimer's disease in "Alzheimer's & Dementia: The Journal of the Alzheimer's Association."

Benzinga · Mar 31, 2022

Benzinga's Top Ratings Upgrades, Downgrades For March 24, 2022

Upgrades

Benzinga · Mar 24, 2022

LGVN: Longeveron Continues to Make Progress

By Brad Sorensen, CFA NASDAQ:LGVN READ THE FULL LGVN RESEARCH REPORT

Benzinga · Mar 11, 2022

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga · Jan 26, 2022

LGVN: Using Cellular Technology to Ease Major Medical Issues

By Brad Sorensen, CFA NASDAQ:LGVN READ THE FULL LGVN RESEARCH REPORT

Coverage From

People

Brad Sorensen

20 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.